title: Oral clindamycin in the treatment of acute uncomplicated falciparum malaria.
abstract: Clinical trials on oral clindamycin as an antimalarial in hospitalized patients and residents of endemic communities were conducted in the Philippines between May 1984 and December 1985. Seven and 9 qualified subjects in hospital were treated with 300 mg (regimen A) and 600 mg (regimen B) respectively, twice daily for 5 days. Eighteen patients seen at a rural health unit were given the lower dosage. On the basis of the 28-day extended in vivo test of WHO, P. falciparum in all but one patient showed susceptibility to the drug as a blood schizontocide hence, the clinical cure of malaria. Side effects were few and self-limiting. Ten other patients on regimen A were cured within the 7- and/or 28-day extended test period. Clindamycin per se is currently one of the few alternatives in the treatment of clinically moderate drug-resistant malaria.
authors.affiliation: Research Institute for Tropical Medicine, Department of Health, Alabang, Muntinlupa, Metro Manila, Philippines.
authors.forename: N P
authors.initials: NP
authors.lastname: Salazar
authors.forename: M C
authors.initials: MC
authors.lastname: Saniel
authors.forename: M H
authors.initials: MH
authors.lastname: Estoque
authors.forename: F A
authors.initials: FA
authors.lastname: Talao
authors.forename: D G
authors.initials: DG
authors.lastname: Bustos
authors.forename: L P
authors.initials: LP
authors.lastname: Palogan
authors.forename: A I
authors.initials: AI
authors.lastname: Gabriel
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D002981:Clindamycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008288:Malaria / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D010270:Parasite Egg Count; D010963:Plasmodium falciparum; D011446:Prospective Studies
chemical_list: D002981:Clindamycin